We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 3,938

Argan powder linked to occupational asthma
  • Shook Hardy & Bacon LLP
  • European Union
  • September 12 2013

A small study, presented September 9, 2013, at the European Respiratory Society Annual Congress in Barcelona, has reportedly revealed that argan

Impact of the draft EC data protection Regulation on the life sciences sector
  • Taylor Wessing
  • European Union
  • July 30 2013

The draft EC data protection Regulation (Regulation) proposes a number of changes to the EU data protection regime which, if adopted, will have

EFPIA leads the self-regulation charge to try to avoid government-imposed transparency
  • Porzio Bromberg & Newman PC
  • European Union
  • July 24 2013

As the worldwide trend toward governmentimposed transparency in the relationships between life sciences companies and healthcare professionals

Current issues in lifesciences
  • CMS Cameron McKenna
  • Czech Republic, European Union
  • January 11 2012

The lifescience sector is driven by development and innovation

Challenge to seclusion policy on the basis of human rights
  • Mills & Reeve LLP
  • European Union, United Kingdom
  • September 17 2012

Following an unsuccessful application to the House of Lords, Colonel Munjaz (a patient detained under the Mental Health Act 1983) challenged the legality of Ashworth Hospital’s seclusion policy on the grounds that it violated his human rights as set out in the European Convention on Human Rights

EU Proposal for a Regulation on Medical Devices in the field of active implantable devices: an overview of the impact
  • Italy Legal Focus - Studio Legale Bernascone & Soci
  • European Union
  • March 18 2013

The Proposal attempts to create a robust regulatory framework which will aim at ensuring a greater level of safety of medical devices, enhanced

AstraZeneca v European Commission, Case c-45710 P
  • White & Case LLP
  • European Union
  • December 10 2012

On 6 December 2012, the European Court of Justice upheld the judgment of the General Court, which found that AstraZeneca abused its dominant position on the market for proton pump inhibitors by misleading patent authorities and misusing the regulatory system in order to prevent generic competition against its anti-ulcer medicine, Losec (omeprazole), in certain markets

AstraZeneca judgment: don’t game the system
  • CMS Cameron McKenna
  • European Union
  • December 12 2012

In a long-awaited judgment dated 6 December 2012, the European Court of Justice (ECJ) has confirmed that certain brand protection strategies may infringe the EU competition rules

Regulating biosimilars: the three guidelines
  • Taylor Wessing
  • European Union
  • July 26 2013

The regulation of similar biological medicinal products ("biosimilars") is governed by article 10(4) of Directive 200183 as amended, supplemented by

Clinical studies the EMA's new approach to transparency
  • Norton Rose Fulbright LLP
  • European Union
  • October 16 2014

Following a consultation which began in November 2012, the European Medicines Agency (EMA) has recently adopted a new policy for the proactive